LOBBYIST

Michael Woody

← Back to lobbyists

63ACTIVITIES

1ORGS REPRESENTED

70BILLS

Organizations represented

Orgs whose LD-2 filings list Michael as an active lobbyist, sorted by activity volume.

Pharmaceutical Research and Manufacturers of America (PhRMA)63 activities

Bills they file on

S. 229633 mentions

S. 265824 mentions

H.R. 394413 mentions

H.R. 412113 mentions

H.R. 421313 mentions

S. 225613 mentions

S. 4313 mentions

S. 70813 mentions

S. 104013 mentions

S. 104113 mentions

S. 109513 mentions

S. 109613 mentions

S. 109713 mentions

S. 154613 mentions

S. 155313 mentions

+ 55 more bills referenced in their activities

Topics in Filings

Policy topics Michael files on across all their LD-2 activities.

One Big Beautiful Bill Act×39

Rural Development×28

RESTORE Patent Rights Act×26

Inflation Reduction Act×26

Drug cost and pricing policy×26

Big Savings Act×24

Supply chain policy×23

BIOSECURE Act×22

Most Favored Nation×22

Biopharmaceutical innovation policy×21

FDA Modernization×14

Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×13

Show all 89 topics (+77 more) ▾

Res. 566: Providing for consideration of the Senate amendment to the bill×13

Skinny Labels×13

Affordable Prescriptions for Patients Act×13

Stop STALLING Act×13

Preserve Access to Affordable Generics and Biosimilars Act×13

Interagency Patent Coordination and Improvement Act×13

Bayh-Dole march-in rights policy×13

Patent thicket policy×13

AI patent policy×13

Patent eligibility policy×13

Post-grant proceeding policy×13

Patent submission policy×13

Modernizing and Ensuring PBM Accountability×13

Medication Affordability and Patent Integrity Act×13

Biosimilar Red Tape Elimination Act×13

Accountability, and Integrity Now and for the Future×13

Vaccine policy×13

Pharmacy Benefit Manager reform×13

Drug importation policy×13

FDA policy×13

Orphan Drug Act×13

Compounding policy×13

Clinical trial policy×13

Issues 340B drug discount program rebate and policy×13

Biosimilar approval and reimbursement policy×13

Artificial intelligence policy×13

Part D redesign and policy×13

Part B policy×13

Medicare rebate policy×13

Center for Medicare and Medicaid Innovation×13

Medicaid rebate policy×13

Stopping Pharmas Ripoffs and Drug Savings For All Act×12

Bipartisan Health Care Act×12

IRA price negotiation expansion policy×12

MAHA Commission Report×12

Make Our Children Healthy Again Competition policy×12

Issues 340B rebate pilot program Patient assistance program policy×12

Biosimilars Access and Affordability Act×12

Legislative Branch×11

Patent fee policy×11

PBM Price Transparency and Accountability Act×11

Mikaela Naylon Give Kids a Chance Act×11

PBM Reform×11

HELP Copays Act×11

Antimicrobial resistance policy×11

GENErating cost Reductions for U.S×11

Medicare Against Rising Drugs Costs×11

Energy and Water Development×10

Military Construction and Veterans Affairs, and Extensions Act, 2026×10

Government funding policy×10

CLEAR LABELS Act×10

Most Favored Patients Act×10

FAIR ACT×10

SECURE Rx Act×10

International intellectual property and market access policy×10

Pricing and reimbursement policy×10

WTO TRIPS waiver policy×10

China outbound investment policy×10

US-UK Framework Agreement×10

Science, and Related Agencies Appropriations Act, 2026×3

User fee issues×3

Patent use codes policy×2

Give Kids a Chance Act×2

Antimicrobial resistance×2

Military Construction×1

Expedited Acccess to Biosimilars Act×1

MAPS Act×1

Orphan Cures Act×1

Prescription Information Modernization×1

Accelerated approval policy×1

Competition policy×1

Patient assistance program policy×1

Drug shortages policy×1

Insulin policy×1

Medicaid waiver policy×1

MVP Act×1

Open Payments Expansion Act×1

Issue mix

LDA general-issue codes weighted by activity count.

Budget/Appropriations14

Health Issues13

Medicare/Medicaid13

Trade (domestic/foreign)10